PL1755671T3 - Terapia raka opornego na platynę - Google Patents

Terapia raka opornego na platynę

Info

Publication number
PL1755671T3
PL1755671T3 PL05761257T PL05761257T PL1755671T3 PL 1755671 T3 PL1755671 T3 PL 1755671T3 PL 05761257 T PL05761257 T PL 05761257T PL 05761257 T PL05761257 T PL 05761257T PL 1755671 T3 PL1755671 T3 PL 1755671T3
Authority
PL
Poland
Prior art keywords
platinum
therapy
resistant cancer
cancer
resistant
Prior art date
Application number
PL05761257T
Other languages
English (en)
Polish (pl)
Inventor
Stephen M Kelsey
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1755671(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1755671T3 publication Critical patent/PL1755671T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL05761257T 2004-06-16 2005-06-15 Terapia raka opornego na platynę PL1755671T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58033304P 2004-06-16 2004-06-16
PCT/US2005/021286 WO2006007398A1 (en) 2004-06-16 2005-06-15 Therapy of platinum-resistant cancer
EP05761257A EP1755671B1 (en) 2004-06-16 2005-06-15 Therapy of platinum-resistant cancer

Publications (1)

Publication Number Publication Date
PL1755671T3 true PL1755671T3 (pl) 2013-05-31

Family

ID=35432102

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05761257T PL1755671T3 (pl) 2004-06-16 2005-06-15 Terapia raka opornego na platynę

Country Status (27)

Country Link
US (2) US20060013819A1 (OSRAM)
EP (1) EP1755671B1 (OSRAM)
JP (3) JP2008503476A (OSRAM)
KR (3) KR20130038407A (OSRAM)
CN (2) CN101014366A (OSRAM)
AR (1) AR049305A1 (OSRAM)
AU (2) AU2005262459B2 (OSRAM)
BR (1) BRPI0511377A (OSRAM)
CA (1) CA2567808C (OSRAM)
DK (1) DK1755671T3 (OSRAM)
ES (1) ES2398689T3 (OSRAM)
GT (1) GT200500155A (OSRAM)
IL (1) IL179401A (OSRAM)
JO (1) JO2794B1 (OSRAM)
MX (1) MXPA06014687A (OSRAM)
MY (1) MY163024A (OSRAM)
NO (1) NO20070243L (OSRAM)
NZ (1) NZ551376A (OSRAM)
PA (1) PA8637101A1 (OSRAM)
PE (1) PE20060461A1 (OSRAM)
PL (1) PL1755671T3 (OSRAM)
RU (1) RU2403065C2 (OSRAM)
SI (1) SI1755671T1 (OSRAM)
SV (1) SV2006002143A (OSRAM)
TW (1) TWI375564B (OSRAM)
WO (1) WO2006007398A1 (OSRAM)
ZA (1) ZA200610132B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
TWI441646B (zh) * 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
CA2596133C (en) * 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2009539836A (ja) * 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
PL2132573T3 (pl) * 2007-03-02 2014-09-30 Genentech Inc Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2618146B1 (en) 2008-02-25 2015-06-17 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
JP5497887B2 (ja) 2009-04-07 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−２／抗ｃ−Ｍｅｔ抗体
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US8591942B2 (en) * 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
EP2513148B1 (en) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
MX2012009554A (es) * 2010-02-23 2012-11-23 Hoffmann La Roche Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
CA2835203A1 (en) * 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
JP6186575B2 (ja) * 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
FI4241849T3 (fi) 2011-10-14 2024-11-12 Hoffmann La Roche Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
MX365139B (es) 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
RU2627185C1 (ru) 2012-03-16 2017-08-03 Коваген Аг Новые связывающие молекулы с противоопухолевой активностью
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
WO2014208760A1 (ja) * 2013-06-27 2014-12-31 国立大学法人九州大学 抗がんモノクローナル抗体及びその製造方法
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
ES2984592T3 (es) 2015-05-30 2024-10-30 Hoffmann La Roche Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2
US9770462B2 (en) 2015-10-05 2017-09-26 National Cheng Kung University Method of treating ovarian, tubal and peritoneal cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
RU2738167C1 (ru) * 2020-06-08 2020-12-09 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии
CN115916834A (zh) 2020-06-29 2023-04-04 基因泰克公司 帕妥珠单抗加曲妥珠单抗的固定剂量组合

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
JP3442784B2 (ja) 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド キナーゼ受容体活性化検定法
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
IL138034A0 (en) * 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
KR20010043323A (ko) * 1998-05-06 2001-05-25 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
PT1189634E (pt) * 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
KR100850389B1 (ko) * 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
NZ517150A (en) * 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1282443B1 (en) * 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
GB0215593D0 (en) * 2002-07-05 2002-08-14 Univ Leeds New anticancer drugs
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
AU2005249205A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an EGFR-inhibitor
KR20110050567A (ko) * 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
TWI441646B (zh) * 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
CA2596133C (en) * 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US9135948B2 (en) 2009-07-03 2015-09-15 Microsoft Technology Licensing, Llc Optical medium with added descriptor to reduce counterfeiting

Also Published As

Publication number Publication date
WO2006007398A9 (en) 2007-02-01
JP2015157831A (ja) 2015-09-03
AU2005262459A1 (en) 2006-01-19
SI1755671T1 (sl) 2013-03-29
ZA200610132B (en) 2009-08-26
BRPI0511377A (pt) 2007-12-04
AU2005262459B2 (en) 2010-12-09
MXPA06014687A (es) 2007-02-12
TWI375564B (en) 2012-11-01
CN105194667A (zh) 2015-12-30
JO2794B1 (en) 2014-03-15
DK1755671T3 (da) 2013-03-25
KR101517715B1 (ko) 2015-05-04
JP2013014611A (ja) 2013-01-24
WO2006007398A1 (en) 2006-01-19
PA8637101A1 (es) 2006-05-16
SV2006002143A (es) 2006-01-26
CA2567808A1 (en) 2006-01-19
HK1102757A1 (en) 2007-12-07
TW200610538A (en) 2006-04-01
AR049305A1 (es) 2006-07-12
NO20070243L (no) 2007-01-15
AU2011200947A1 (en) 2011-03-24
ES2398689T3 (es) 2013-03-21
RU2403065C2 (ru) 2010-11-10
EP1755671A1 (en) 2007-02-28
US20060013819A1 (en) 2006-01-19
JP2008503476A (ja) 2008-02-07
IL179401A0 (en) 2007-05-15
CN101014366A (zh) 2007-08-08
EP1755671B1 (en) 2012-12-12
GT200500155A (es) 2006-05-15
PE20060461A1 (es) 2006-08-04
IL179401A (en) 2012-12-31
KR20070029804A (ko) 2007-03-14
US20120107391A1 (en) 2012-05-03
RU2007101378A (ru) 2008-07-27
MY163024A (en) 2017-07-31
NZ551376A (en) 2009-11-27
KR20140012197A (ko) 2014-01-29
KR20130038407A (ko) 2013-04-17
CA2567808C (en) 2014-03-18

Similar Documents

Publication Publication Date Title
IL179401A0 (en) Therapy of platinum-resistant cancer
IL188746A0 (en) Treatment of cancer
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1814544A4 (en) CANCER TREATMENTS
IL186662A0 (en) Combination cancer therapy with
IL188430A0 (en) Treatment of tumors
PT1830847E (pt) Tratamento para o cancro
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
PL1858929T3 (pl) Diagnostyka raka gruczołu krokowego
GB0428187D0 (en) Cancer treatment
IL161899A0 (en) Kit for treatment of cancer
IL189376A0 (en) Combinations comprising dmxaa for the treatment of cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0329416D0 (en) Treatment of cancer
GB0520067D0 (en) Treatment of cancer
GB0410379D0 (en) Treatment of cancer
IL180709A0 (en) Treatment of tumours
GB0404675D0 (en) Cancer treatment
GB0423273D0 (en) Treatment of cancer
GB0507685D0 (en) Cancer treatment
GB0414885D0 (en) Cancer therapy
IL180460A0 (en) Treatment of cancer
GB0420845D0 (en) Treatment of cancer
GB0421734D0 (en) Treatment of cancer